当前位置: X-MOL 学术Biometals › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Biguanide is a modifiable pharmacophore for recruitment of endogenous Zn2+ to inhibit cysteinyl cathepsins: review and implications.
Biometals ( IF 4.1 ) Pub Date : 2019-05-01 , DOI: 10.1007/s10534-019-00197-1
Thomas D Lockwood 1
Affiliation  

Excessive activities of cysteinyl cathepsins (CysCts) contribute to the progress of many diseases; however, therapeutic inhibition has been problematic. Zn2+ is a natural inhibitor of proteases with CysHis dyads or CysHis(Xaa) triads. Biguanide forms bidentate metal complexes through the two imino nitrogens. Here, it is discussed that phenformin (phenylethyl biguanide) is a model for recruitment of endogenous Zn2+ to inhibit CysHis/CysHis(X) peptidolysis. Phenformin is a Zn2+-interactive, anti-proteolytic agent in bioassay of living tissue. Benzoyl-L-arginine amide (BAA) is a classical substrate of papain-like proteases; the amide bond is scissile. In this review, the structures of BAA and the phenformin-Zn2+ complex were compared in silico. Their chemistry and dimensions are discussed in light of the active sites of papain-like proteases. The phenyl moieties of both structures bind to the "S2" substrate-binding site that is typical of many proteases. When the phenyl moiety of BAA binds to S2, then the scissile amide bond is directed to the position of the thiolate-imidazolium ion pair, and is then hydrolyzed. However, when the phenyl moiety of phenformin binds to S2, then the coordinated Zn2+ is directed to the identical position; and catalysis is inhibited. Phenformin stabilizes a "Zn2+ sandwich" between the drug and protease active site. Hundreds of biguanide derivatives have been synthesized at the 1 and 5 nitrogen positions; many more are conceivable. Various substituent moieties can register with various arrays of substrate-binding sites so as to align coordinated Zn2+ with catalytic partners of diverse proteases. Biguanide is identified here as a modifiable pharmacophore for synthesis of therapeutic CysCt inhibitors with a wide range of potencies and specificities. Phenformin-Zn2+ Complex.

中文翻译:

双胍是可修饰的药效基团,用于募集内源性Zn2 +以抑制半胱氨酸组织蛋白酶:综述和意义。

半胱氨酸组织蛋白酶(CysCts)的过度活动导致许多疾病的发展;然而,治疗抑制是有问题的。Zn2 +是与CysHis二联体或CysHis(Xaa)三联体蛋白酶的天然抑制剂。双胍通过两个亚氨基形成二齿金属络合物。在这里,讨论了苯乙双胍(苯乙双胍)是内源性Zn2 +募集以抑制CysHis / CysHis(X)肽分解的模型。苯乙双胍是在活组织生物测定中与Zn2 +相互作用的抗蛋白水解剂。苯甲酰基-L-精氨酸酰胺(BAA)是木瓜蛋白酶样蛋白酶的经典底物;酰胺键易裂。在这篇综述中,通过计算机比较了BAA和苯乙双胍-Zn2 +复合物的结构。根据木瓜蛋白酶样蛋白酶的活性位点讨论了它们的化学性质和尺寸。两个结构的苯基部分都结合了许多蛋白酶典型的“ S2”底物结合位点。当BAA的苯基部分与S2结合时,可裂开的酰胺键被引导至硫醇盐-咪唑鎓离子对的位置,然后被水解。但是,当苯乙双胍的苯基部分与S2结合时,则配位的Zn2 +指向相同的位置。并且催化被抑制。苯乙双胍可稳定药物和蛋白酶活性位点之间的“ Zn2 +三明治”。在1和5个氮原子位置上已合成了数百个双胍衍生物。可以想象更多。各种取代基部分可与底物结合位点的各种阵列配准,以使配位的Zn2 +与各种蛋白酶的催化配偶体对齐。双胍在这里被鉴定为可合成的药效基团,用于合成具有广泛效价和特异性的治疗性CysCt抑制剂。苯乙双胍-Zn2 +复合物。
更新日期:2019-11-01
down
wechat
bug